Stay updated on Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial page
- Check5 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check27 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check56 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check63 days agoChange DetectedDifference0.5%
- Check70 days agoChange DetectedThe page has removed detailed descriptions of a Phase 1 study for a treatment of relapsed/refractory diffuse large B-cell lymphoma, including inclusion and exclusion criteria, while adding a new revision number and a specific EudraCT number.SummaryDifference36%
Stay in the know with updates to Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Betalutin in Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial page.